Armata Pharma director Daniel Gilmer files Form 3

Armata Pharmaceuticals, Inc. filed an initial insider ownership report for Daniel B. Gilmer, who is identified as a director of the company.

Rhea-AI Filing Summary

Armata Pharmaceuticals, Inc. filed an initial insider ownership report for Daniel B. Gilmer, who is identified as a director of the company. The Form 3 report shows no reported transactions, acquisitions, dispositions, or derivative positions at the time of this filing.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Daniel B. Gilmer’s Form 3 filing for ARMP indicate?

The Form 3 filing for ARMP shows Daniel B. Gilmer as a director and reporting person. It is an initial insider ownership report and, in this case, lists no transactions, acquisitions, dispositions, or derivative securities at the time of filing.

Does the ARMP Form 3 for Daniel B. Gilmer show any stock purchases or sales?

No, the ARMP Form 3 for Daniel B. Gilmer reports no stock purchases or sales. The transaction summary shows zero buy, sell, acquire, dispose, gift, tax-withholding, or restructuring transactions, reflecting only his status as a director at Armata Pharmaceuticals.

What insider role does Daniel B. Gilmer hold at Armata Pharmaceuticals (ARMP)?

Daniel B. Gilmer is identified as a director of Armata Pharmaceuticals (ARMP). The Form 3 indicates he is not listed as an officer or a ten-percent owner, and it provides his status for insider reporting without detailing any current securities transactions.

Are there any derivative securities reported in Daniel B. Gilmer’s ARMP Form 3?

No derivative securities are reported in Daniel B. Gilmer’s ARMP Form 3. The derivative summary is empty and the transaction summary shows zero derivative transactions, indicating no options, warrants, or similar instruments are disclosed in this initial insider filing.

How many insider transactions are summarized in the ARMP Form 3 for Daniel B. Gilmer?

The ARMP Form 3 for Daniel B. Gilmer summarizes zero insider transactions. All transaction counts, including buys, sells, exercises, gifts, tax withholding, and restructurings, are listed as zero, emphasizing that this filing only establishes his reporting status as a director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/28/2026 - 04:22 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Gilmer Daniel B.

(Last) (First) (Middle)

5005 MCCONNELL AVENUE

(Street)

LOS ANGELES CALIFORNIA 90066

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/24/2026

3. Issuer Name and Ticker or Trading Symbol
Armata Pharmaceuticals, Inc. [ ARMP ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Daniel Gilmer	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)